Both a somatic mutation (chr19:g.51363764A>C) and a germline mutation (rs1803136) in the 3′UTR of KLK3, a gene whose expression is commonly used as a diagnostic marker in prostate cancer [48], disrupted predicted target sites for miR-675, miR-138, and miR-210. This evidence concerns the gene KLK3 and prostate carcinoma.